Mark Epstein highlights Preservé breast augmentation experience and surgeon training

Board-certified plastic surgeon Mark D. Epstein, MD, FACS is outlining eight years of Motiva experience, 174 Preservé procedures and a growing surgeon education effort as tissue-preserving breast augmentation gains traction in the United States. The update underscores how clinical research, formal training and surgical tools are shaping the next phase of breast implant surgery.

Why it matters: - Preservé breast augmentation is positioned as a tissue-preserving option for patients and surgeons seeking less disruption of native breast tissue during implant placement. - The technique is tied to Motiva breast implants, which received U.S. Food and Drug Administration approval on Sept. 26, 2024, the first new breast implant approval in the U.S. since February 2013. - Dr. Epstein’s work links clinical research, surgeon training and device innovation in one of the most closely watched areas of aesthetic breast surgery.

What happened: - Board-certified plastic surgeon Mark D. Epstein, MD, FACS, detailed his experience with Motiva technology, which began in May 2018. - Dr. Epstein was one of 22 principal investigators in the U.S. FDA clinical trial evaluating Motiva breast implants. - He enrolled 73 patients in that study, the highest enrollment among participating investigators. - After FDA approval, Dr. Epstein continued as an investigator in the Motiva post-approval study. - He later became one of the first 36 plastic surgeons in the U.S. to receive formal training in the Preservé breast augmentation technique. - Dr. Epstein has now performed 174 Preservé breast augmentation procedures. - His practice in Hauppauge, New York, now serves as both a patient destination and an educational site for surgeons learning the technique.

The details: - Preservé breast augmentation emphasizes preservation of native breast tissue and aims to minimize disruption of important anatomical structures during implant placement. - The procedure combines implant technology with refined surgical techniques intended to reduce tissue trauma while still delivering natural-appearing aesthetic outcomes in appropriately selected patients. - Dr. Epstein’s broader surgical philosophy has focused on reduced tissue trauma, thoughtful innovation and enhanced recovery over more than three decades in aesthetic plastic surgery. - He also created the Epstein Breast Preservation Channel Dilator, a specialized surgical instrument designed to help create a channel atraumatically during Preservé breast augmentation. - Dr. Epstein serves as one of 12 national Preservé trainers. - He has trained 62 plastic surgeons from 14 states and the District of Columbia through educational programs, workshops and surgical training sessions. - In his public comments, Dr. Epstein said his involvement with Motiva has let him follow the technology from FDA clinical investigation to routine clinical practice. - Dr. Epstein said his goal is to evaluate how tissue-preserving surgical principles may benefit appropriately selected patients.

Between the lines: - The announcement shows how manufacturers, investigators and surgeon trainers are building adoption around a newer surgical approach, not just a new implant. - Dr. Epstein’s dual role as a researcher and educator gives his practice added visibility as Preservé expands. - The focus on specialized instrumentation suggests the technique is still being refined for broader clinical use. - The surgeon-training network also signals that Preservé is moving from early adoption toward more structured dissemination.

What's next: - Dr. Epstein plans to continue evaluating clinical outcomes, expand surgeon education programs and develop additional tissue-preservation innovations. - Preservé’s wider growth will likely depend on surgeon training, patient selection and ongoing outcome data. - More information is available from the practice website.

The bottom line: - Preservé breast augmentation is advancing through a mix of clinical research, hands-on training and surgical tool development, with Dr. Epstein positioned as a key U.S. early adopter and educator.